LAMA2-related Muscular Dystrophy Brain Study

This study has been withdrawn prior to enrollment.
Sponsor:
Collaborator:
Congenital Muscle Disease International Registry
Information provided by (Responsible Party):
Sabine de Chastonay, Cure CMD
ClinicalTrials.gov Identifier:
NCT01952028
First received: September 19, 2013
Last updated: January 15, 2014
Last verified: January 2014
  Purpose

Laminin alpha-2 (LAMA2)-related muscular dystrophy (LAMA2-MD, Merosin Deficient CMD) is a form of congenital muscular dystrophy (CMD). A person with LAMA2-MD will have changes on brain imaging (MRI), a decrease or absence of the protein merosin (laminin 211) on muscle or skin biopsy and changes in the LAMA2 gene that are inherited from both parents. Several studies have described the changes on brain MRI. Brain changes on MRI do not correlate with the partial reduction or absence of merosin on muscle or skin biopsy. 8-30% of people with LAMA2-MD develop seizures. The types of seizures, electroencephalogram changes and common treatment regimens have not been characterized. This study will review the magnetic resonance imaging (MRI) changes, determine whether certain brain MRI changes are linked to seizures and define the common seizure treatment regimens.


Condition
LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: A LAMA2-related Muscular Dystrophy Study: Brain Magnetic Resonance Imaging (MRI)and Brain Electrophysiology Evaluation

Resource links provided by NLM:


Further study details as provided by Cure CMD:

Primary Outcome Measures:
  • Identify and grade the structural brain abnormalities observed on MRI [ Time Frame: up to 5 months ] [ Designated as safety issue: No ]
    Both single and longitudinal brain MRIs will be retrieved with patient consent from hospitals within the United States. Two trained neuroradiologists will evaluate de-identified brain MRIs using a pre-determined scoring system to identify and classify structural abnormalities.


Secondary Outcome Measures:
  • Seizure History [ Time Frame: up to 8 months ] [ Designated as safety issue: No ]
    To obtain a seizure history on all individuals with LAMA2-MD who have had a seizure, including: type of seizures, age of seizure onset, seizure frequency, need for mechanical ventilation, seizure medications, and need for emergency room (ER) visit or hospitalization.

  • Evaluation of baseline and diagnostic electroencephalograms [ Time Frame: up to 8 months ] [ Designated as safety issue: No ]
    Both baseline and diagnostic electroencephalograms (EEG) will be obtained with patient consent from hospitals within the United States. An epileptologist will review de-identified EEG recordings to identify and classify abnormalities using a predetermined scoring system.

  • Examine the association between brain MRI structural abnormalities and EEG findings [ Time Frame: up to 11 months ] [ Designated as safety issue: No ]
    Compare the frequency of various grades of brain MRI abnormalities in individuals with LAMA2-MD with and without seizures. Identify any association between MRI abnormality and type of seizure.


Enrollment: 0
Study Start Date: November 2013
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Detailed Description:

LAMA2-MD is a congenital muscular dystrophy (CMD) subtype caused by mutations in the laminin alpha 2 gene. LAMA2-MD may present clinically as an early onset, severe phenotype or a late onset limb girdle phenotype. The early onset form is most commonly associated with a complete absence of merosin on muscle biopsy with profound neonatal hypotonia, possible respiratory distress and feeding difficulties while the late onset form presents with proximal muscle weakness, contractures and is able to achieve walking. In both early and late onset forms, brain white matter abnormalities have been described on brain MRI and approximately 8-30% develop a seizure disorder. On magnetic resonance (MR) spectroscopy, white matter changes are shown to be due to increased water content rather than areas of demyelination. Both, non-ambulant and ambulant patients may develop respiratory insufficiency requiring non-invasive ventilation and scoliosis.

Although several studies have evaluated the correlation between brain MRI white matter changes and cognition, no studies to date have provided a systematic evaluation of brain imaging, electrophysiologic testing and seizures in patients identified by molecular or immunohistochemical testing to have LAMA2-MD.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

LAMA2-MD

Criteria

Inclusion Criteria:

  • Genetic confirmation of 2 variants in LAMA2 gene OR muscle biopsy with complete absence of merosin
  • Complete authorization to obtain medical records for Congenital Muscle Disease International Registry
  • Complete authorization to obtain medical records for National Institutes of Health (NIH)
  • Reside in United States or Canada
  • Complete registration and intake survey in the Congenital Muscle Disease International Registry

Exclusion Criteria:

- Individuals with LAMA2-MD who have not had a brain MRI

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01952028

Locations
United States, California
CMDIR
San Pedro, California, United States, 90732
Sponsors and Collaborators
Cure CMD
Congenital Muscle Disease International Registry
Investigators
Principal Investigator: Anne Rutkowski, MD, PhD Cure CMD
  More Information

Publications:

Responsible Party: Sabine de Chastonay, PhD, Cure CMD
ClinicalTrials.gov Identifier: NCT01952028     History of Changes
Other Study ID Numbers: CMDIR-003
Study First Received: September 19, 2013
Last Updated: January 15, 2014
Health Authority: United States: Congenital Muscle Disease International Registry (CMDIR)

Keywords provided by Cure CMD:
MDC1A
Congenital Muscular Dystrophy
Merosin Deficient
LAMA2
brain white matter abnormalities
Seizure

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on July 28, 2014